Shopping Cart
Remove All
Your shopping cart is currently empty
Olendalizumab
(Synonyms: Lendalizumab, ALXN1007) Copy Product Info
🥰Excellent
Synonyms: Lendalizumab, ALXN1007
Catalog No. T77107 Copy Product Info
🥰Excellent
Olendalizumab is a humanized monoclonal antibody targeting complement component C5a. Olendalizumab blocks the interaction between C5a and receptor C5aR(CD88) by specifically binding C5a, thus inhibiting C5a-mediated inflammatory reaction and chemotaxis and activation of neutrophils. Olendalizumab is used for inflammatory diseases mediated by complement, such as sepsis, graft-versus-host disease (GVHD) and viral infection (such as COVID-19).
Olendalizumab
Cas No. 2210314-30-8
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 5 mg | Inquiry | Inquiry | Inquiry |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Olendalizumab is a humanized monoclonal antibody targeting complement component C5a. Olendalizumab blocks the interaction between C5a and receptor C5aR(CD88) by specifically binding C5a, thus inhibiting C5a-mediated inflammatory reaction and chemotaxis and activation of neutrophils. Olendalizumab is used for inflammatory diseases mediated by complement, such as sepsis, graft-versus-host disease (GVHD) and viral infection (such as COVID-19). |
| In vitro | In a Gyrolab assay, Olendalizumab demonstrated high specificity as a biotinylated capture reagent (working concentration: 100 µg/mL in Bioaffy wash 1), working alongside AlexaFluor-labeled anti-C5a clone 2942 (4 µg/mL in Rexxip F) to enable precise quantitation of free C5a in human plasma [1]. |
| In vivo | In viral infection models, Olendalizumab acted as a potent C5a inhibitor to mitigate lung injury mediated by complement components (C3, C5a, C5b-9) and receptors (C3aR, C5aR), specifically blocking the non-silent complement activation triggered by coronaviruses [2]. |
| Synonyms | Lendalizumab, ALXN1007 |
| Reactivity | Virus |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | ComplementproteinC5a |
| Cas No. | 2210314-30-8 |
| Isotype | IgG2SA |
| Storage | Store at low temperature Store at -20°C Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Preview
Related Tags: Olendalizumab in vivo | Olendalizumab in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.